Literature DB >> 33417160

Neuroimaging Biomarkers and Neurocognitive Outcomes in Pediatric Medulloblastoma Patients: a Systematic Review.

Maarten Wauters1, Anne Uyttebroeck1,2, Liesbeth De Waele3, Charlotte Sleurs4, Sandra Jacobs1,2.   

Abstract

Medulloblastoma is a malign posterior fossa brain tumor, mostly occurring in childhood. The CNS-directed chemoradiotherapy treatment can be very harmful to the developing brain and functional outcomes of these patients. However, what the underlying neurotoxic mechanisms are remain inconclusive. Hence, this review summarizes the existing literature on the association between advanced neuroimaging and neurocognitive changes in patients that were treated for pediatric medulloblastoma. The PubMed/Medline database was extensively screened for studies investigating the link between cognitive outcomes and multimodal magnetic resonance (MR) imaging in childhood medulloblastoma survivors. A behavioral meta-analysis was performed on the available IQ scores. A total of 649 studies were screened, of which 22 studies were included. Based on this literature review, we conclude medulloblastoma patients to be at risk for white matter volume loss, more frequent white matter lesions, and changes in white matter microstructure. Such microstructural alterations were associated with lower IQ, which reached the clinical cut-off in survivors across studies. Using functional MR scans, changes in activity were observed in cerebellar areas, associated with working memory and processing speed. Finally, cerebral microbleeds were encountered more often, but these were not associated with cognitive outcomes. Regarding intervention studies, computerized cognitive training was associated with changes in prefrontal and cerebellar activation and physical training might result in microstructural and cortical alterations. Hence, to better define the neural targets for interventions in pediatric medulloblastoma patients, this review suggests working towards neuroimaging-based predictions of cognitive outcomes. To reach this goal, large multimodal prospective imaging studies are highly recommended.

Entities:  

Keywords:  Innovative imaging methods; MRI; Medulloblastoma; Multimodal neuroimaging; Neurocognition; Neurocognitive outcomes; Pediatric; Systematic review

Mesh:

Substances:

Year:  2021        PMID: 33417160     DOI: 10.1007/s12311-020-01225-4

Source DB:  PubMed          Journal:  Cerebellum        ISSN: 1473-4222            Impact factor:   3.847


  79 in total

1.  Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma.

Authors:  Roger J Packer; Amar Gajjar; Gilbert Vezina; Lucy Rorke-Adams; Peter C Burger; Patricia L Robertson; Lisa Bayer; Deborah LaFond; Bernadine R Donahue; MaryAnne H Marymont; Karin Muraszko; James Langston; Richard Sposto
Journal:  J Clin Oncol       Date:  2006-09-01       Impact factor: 44.544

2.  Large cell/anaplastic medulloblastoma is associated with poor prognosis-a retrospective analysis at a single institute.

Authors:  Pin-I Huang; Shih-Chieh Lin; Yi-Yen Lee; Donald Ming-Tak Ho; Wan-Yuo Guo; Kai-Ping Chang; Feng-Chi Chang; Muh-Lii Liang; Hsin-Hung Chen; Yu-Ming Liu; Sang-Hue Yen; Tai-Tong Wong; Yi-Wei Chen
Journal:  Childs Nerv Syst       Date:  2017-05-09       Impact factor: 1.475

Review 3.  Medulloblastoma in young children.

Authors:  Stefan Rutkowski; Bruce Cohen; Jonathan Finlay; Roberto Luksch; Vita Ridola; Dominique Valteau-Couanet; Junichi Hara; Maria-Luisa Garre; Jacques Grill
Journal:  Pediatr Blood Cancer       Date:  2010-04       Impact factor: 3.167

4.  Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children's Cancer Group Study.

Authors:  R J Packer; J Goldwein; H S Nicholson; L G Vezina; J C Allen; M D Ris; K Muraszko; L B Rorke; W M Wara; B H Cohen; J M Boyett
Journal:  J Clin Oncol       Date:  1999-07       Impact factor: 44.544

5.  Alex's Lemonade Stand Foundation Infant and Childhood Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011.

Authors:  Quinn T Ostrom; Peter M de Blank; Carol Kruchko; Claire M Petersen; Peter Liao; Jonathan L Finlay; Duncan S Stearns; Johannes E Wolff; Yingli Wolinsky; John J Letterio; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2015-01       Impact factor: 12.300

6.  Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children's Oncology Group trial A9961.

Authors:  Roger J Packer; Tianni Zhou; Emi Holmes; Gilbert Vezina; Amar Gajjar
Journal:  Neuro Oncol       Date:  2012-10-25       Impact factor: 12.300

Review 7.  Medulloblastoma.

Authors:  Nathan E Millard; Kevin C De Braganca
Journal:  J Child Neurol       Date:  2015-09-02       Impact factor: 1.987

8.  Molecular subgroups of medulloblastoma: the current consensus.

Authors:  Michael D Taylor; Paul A Northcott; Andrey Korshunov; Marc Remke; Yoon-Jae Cho; Steven C Clifford; Charles G Eberhart; D Williams Parsons; Stefan Rutkowski; Amar Gajjar; David W Ellison; Peter Lichter; Richard J Gilbertson; Scott L Pomeroy; Marcel Kool; Stefan M Pfister
Journal:  Acta Neuropathol       Date:  2011-12-02       Impact factor: 17.088

Review 9.  Modern management of medulloblastoma: Molecular classification, outcomes, and the role of surgery.

Authors:  Visish M Srinivasan; Michael G Z Ghali; Robert Y North; Zain Boghani; Daniel Hansen; Sandi Lam
Journal:  Surg Neurol Int       Date:  2016-12-28

10.  Incidence of childhood CNS tumours in Britain and variation in rates by definition of malignant behaviour: population-based study.

Authors:  Charles A Stiller; Anita M Bayne; Aruna Chakrabarty; Tom Kenny; Paul Chumas
Journal:  BMC Cancer       Date:  2019-02-11       Impact factor: 4.430

View more
  1 in total

1.  Neurocognitive function and survival in children with average-risk medulloblastoma treated with hyperfractionated radiation therapy alone: Long-term mature outcomes of a prospective study.

Authors:  Tejpal Gupta; Babusha Kalra; Savita Goswami; Jayita Deodhar; Pallavi Rane; Sridhar Epari; Aliasgar Moiyadi; Archya Dasgupta; Abhishek Chatterjee; Girish Chinnaswamy
Journal:  Neurooncol Pract       Date:  2022-03-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.